Edit Symbol List
Enter up to 25 symbols separated by commas or spaces in the text box below. These symbols will be available during your session for use on applicable pages.
Don't know the stock symbol? Use the
Symbol Lookup tool.
Alphabetize the sort order of my symbols
Investing just got easier…
Sign up now to become a NASDAQ.com member and begin receiving instant notifications when key events occur that affect the stocks you follow.Access Now X
Company Description (as filed with the SEC)
We are a biopharmaceutical company seeking to transform innovation into novel treatments that address the needs of patients by discovering and developing small molecule therapeutics for the treatment of infectious diseases and immune system disorders. We are currently focusing our efforts on developing commercially competitive, short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. Specifically, we are advancing combination regimens containing: * ACH-3102, a NS5A inhibitor, currently in phase II clinical development; * ACH-3422, a NS5B nucleotide polymerase inhibitor, currently in phase I clinical development; and * Sovaprevir, a NS3 protease inhibitor, currently in phase II clinical development. ... More ...
Where does ACHN fit in the risk graph?
|Annual EPS Est:||$-0.7|
|Quarterly EPS Est:||-0.19|